DKK1 and gastric cancer: Clinical trials have been conducted combining DKN‐01, an antibody to DKK1, with tislelizumab and chemotherapy as first‐line treatments for patients with GC and gastroesophageal junction cancer, with a preliminary objective response rate (ORR) of 68% and disease control rate of 100%.